193 related articles for article (PubMed ID: 27231256)
1. Which Cognitive Domains are Improved by Treatment with Vortioxetine?
Harrison JE; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2016 May; 19(10):. PubMed ID: 27231256
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
McIntyre RS; Lophaven S; Olsen CK
Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
McIntyre RS; Harrison J; Loft H; Jacobson W; Olsen CK
Int J Neuropsychopharmacol; 2016 Jun; 19(10):. PubMed ID: 27312740
[TBL] [Abstract][Full Text] [Related]
4. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
6. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
[No Abstract] [Full Text] [Related]
7. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
11. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
[TBL] [Abstract][Full Text] [Related]
12. Vortioxetine: A Review in Cognitive Dysfunction in Depression.
Frampton JE
Drugs; 2016 Nov; 76(17):1675-1682. PubMed ID: 27807822
[TBL] [Abstract][Full Text] [Related]
13. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Huang IC; Chang TS; Chen C; Sung JY
Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
[TBL] [Abstract][Full Text] [Related]
14. Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study.
Kim H; Baik SY; Kim YW; Lee SH
Neuropsychopharmacol Rep; 2022 Mar; 42(1):21-31. PubMed ID: 34894110
[TBL] [Abstract][Full Text] [Related]
15. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
Murthy NV; Xu R; Zhong W; Harvey PD
J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
[TBL] [Abstract][Full Text] [Related]
16. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
[TBL] [Abstract][Full Text] [Related]
17. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms.
Xue L; Bocharova M; Young AH; Aarsland D
J Affect Disord; 2024 Jun; 361():74-81. PubMed ID: 38838790
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
[No Abstract] [Full Text] [Related]
20. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.
Mansur RB; Ahmed J; Cha DS; Woldeyohannes HO; Subramaniapillai M; Lovshin J; Lee JG; Lee JH; Brietzke E; Reininghaus EZ; Sim K; Vinberg M; Rasgon N; Hajek T; McIntyre RS
J Affect Disord; 2017 Jan; 207():114-120. PubMed ID: 27721184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]